Opportunities Preloader

Please Wait.....

Report

Global Genitourinary Drugs Market Report and Forecast 2023-2031

Market Report I 2023-05-06 I 147 Pages I EMR Inc.

Global Genitourinary Drugs Market Report and Forecast 2023-2031
Global Genitourinary Drugs Market Outlook
The global genitourinary drugs market value was USD 47 billion in 2022, driven by the increasing prevalence of urinary tract infections across the globe. The market size is anticipated to grow at a CAGR of 3.1% during the forecast period of 2023-2031 to achieve a value of USD 61.9 billion by 2031.

Genitourinary Drugs Introduction
Genitourinary drugs refer to medications used to treat conditions related to the urinary and reproductive systems. These drugs are used to treat a wide range of conditions such as urinary tract infections, erectile dysfunction, prostate cancer, and others.
There are several classes of genitourinary drugs including antibiotics, antifungal agents, hormone therapy, and others. Some of the commonly prescribed genitourinary drugs include sildenafil (Viagra), tamsulosin (Flomax), finasteride (Proscar), and trimethoprim/sulfamethoxazole (Bactrim).
The market for genitourinary drugs is driven by factors such as increasing prevalence of urinary tract infections, rising demand for erectile dysfunction drugs, growing geriatric population, and increasing incidence of genitourinary cancers. The market is also witnessing growth due to the increasing focus on research and development activities by pharmaceutical companies, as well as the growing demand for personalized medicine.
The key trends in the genitourinary drugs market include the increasing adoption of combination therapies, growing focus on the development of biologics and targeted therapies, and the rise in demand for generic drugs. Additionally, there is an increasing trend towards the use of novel drug delivery systems such as transdermal patches, nasal sprays, and injectables, which offer improved efficacy and convenience to patients.
Genitourinary Drugs Market Scenario
Genitourinary drugs refer to a class of medications used to treat conditions affecting the reproductive and urinary systems. These drugs may be used to treat conditions such as urinary tract infections, prostate cancer, erectile dysfunction, and other urological disorders. Genitourinary drugs can be administered orally, topically, or through injection.
The market for genitourinary drugs is driven by the growing prevalence of urological disorders such as urinary tract infections and prostate cancer. Additionally, the increasing aging population, rising healthcare expenditure, and growing awareness about genitourinary disorders are also contributing to the growth of the market. However, factors such as patent expiration of drugs and the presence of alternative therapies may restrain market growth.

Genitourinary Drugs Market Segmentations
Market Breakup by Indications
- Prostate Cancer
- Ovarian Cancer
- Bladder Cancer
- Cervical Cancer
- Renal Cancer
- Erectile Dysfunction
- Urinary Tract Infections
- Overactive Bladder
- Sexually Transmitted Diseases
- Interstitial Cystitis
- Hematuria
- Benign Prostatic Hyperplasia
- Others

Market Breakup by Drug Type
- Hormonal Therapy
- Impotence Agents
- Uterine Relaxants
- Urinary Antispasmodics
- Urinary pH Modifiers
- Uterine Stimulants
- Miscellaneous Genitourinary
- Tract Agents
- Others

Market Breakup by Route of Administration
- Oral
- Parentals

Market Breakup by Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy

Market Breakup by Region

- North America
- United States of America
- Canada

- Europe
- United Kingdom
- Germany
- France
- Italy
- Others

- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others

- Latin America
- Brazil
- Argentina
- Mexico
- Others

- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

Key Trends in the Genitourinary Drugs Market
Some of the key trends in the Genitourinary Drugs market are:
- Increasing prevalence of urological and genital disorders: The rising incidence of urological and genital disorders, including urinary tract infections, erectile dysfunction, prostate cancer, and infertility, is driving the demand for genitourinary drugs.
- Growing aging population: The aging population is more susceptible to genitourinary disorders such as incontinence and prostate cancer, which is contributing to the growth of the market.
- Increasing adoption of combination therapies: Combination therapies, which involve the use of multiple drugs to treat a disease, are becoming more popular in the treatment of genitourinary disorders. This approach is expected to improve treatment outcomes and drive market growth.
- Rise in the number of drug approvals: The FDA and other regulatory agencies have approved several new drugs for the treatment of genitourinary disorders in recent years. This is contributing to the growth of the market by expanding the treatment options available to healthcare providers.
- Growing demand for personalized medicine: Personalized medicine, which involves tailoring treatment to an individual's specific needs based on their genetic makeup, is gaining popularity in the genitourinary drugs market. This approach is expected to improve treatment outcomes and drive market growth in the coming years.

Genitourinary Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer Inc.
- Astellas Pharma.
- Allergan
- GlaxoSmithKline plc.
- Antares Pharma
- Eli Lilly and Company
- Bayer AG, Merck KGaA
- Abbott
- Bristol-Myers Squibb Company
- Genentech
- F. Hoffman-La Roche Ltd.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- AstraZeneca
- Advanz Pharmaceutical


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Genitourinary Drugs Market Overview
3.1 Global Genitourinary Drugs Market Historical Value (2016-2022)
3.2 Global Genitourinary Drugs Market Forecast Value (2023-2031)
4 Global Genitourinary Drugs Market Landscape
4.1 Global Genitourinary Drugs Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Genitourinary Drugs Product Landscape
4.2.1 Analysis by Indications
4.2.2 Analysis by Drug Type
4.2.3 Analysis by Distribution Channel
5 Global Genitourinary Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Genitourinary Drugs Market Segmentation
6.1 Global Genitourinary Drugs Market by Indications
6.1.1 Market Overview
6.1.2 Prostate Cancer
6.1.3 Ovarian Cancer
6.1.4 Bladder Cancer
6.1.5 Cervical Cancer
6.1.6 Renal Cancer
6.1.7 Erectile Dysfunction
6.1.8 Urinary Tract Infections
6.1.9 Overactive Bladder
6.1.10 Sexually Transmitted Diseases
6.1.11 Interstitial Cystitis
6.1.12 Hematuria
6.1.13 Benign Prostatic Hyperplasia
6.1.14 Others
6.2 Global Genitourinary Drugs Market by Drug Type
6.2.1 Market Overview
6.2.2 Hormonal Therapy
6.2.3 Impotence Agents
6.2.4 Uterine Relaxants
6.2.5 Urinary Antispasmodics
6.2.6 Urinary pH Modifiers
6.2.7 Uterine Stimulants
6.2.8 Miscellaneous Genitourinary
6.2.9 Tract Agents
6.2.10 Others
6.3 Global Genitourinary Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parentals
6.4 Global Genitourinary Drugs Market by Distribution Channel
6.4.1 Market Overview
6.4.2 Hospital Pharmacy
6.4.3 Online Pharmacy
6.4.4 Retail Pharmacy
6.5 Global Genitourinary Drugs Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Genitourinary Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Genitourinary Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Genitourinary Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Genitourinary Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Genitourinary Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 Pfizer Inc.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Astellas Pharma.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Allergan
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 GlaxoSmithKline plc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Antares Pharma
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Eli Lilly and Company
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Bayer AG, Merck KGaA
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Abbott
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Bristol-Myers Squibb Company
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Genentech
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 F. Hoffman-La Roche Ltd.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Novartis AG
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Teva Pharmaceutical Industries Ltd.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 AstraZeneca
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
18.15 Advanz Pharmaceutical
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.15.5 Certifications
19 Global Genitourinary Drugs Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE